证券代码：688278 证券简称：特宝生物 公告编号：2026-007 厦门特宝生物工程股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定执行。 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 2 月 11 日 14 点 00 分 召开地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 11 日 至2026 年 2 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30， ...

证券代码：688278 证券简称：特宝生物 公告编号：2026-002 厦门特宝生物工程股份有限公司 第九届董事会第十六次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 厦门特宝生物工程股份有限公司（以下简称"公司"）第九届董事会第十六次 会议于 2026 年 1 月 26 日以现场会议结合通讯表决的方式召开。本次会议已于 2026 年 1 月 16 日通过邮件方式通知公司全体董事。本次会议由董事长孙黎先生主持，会 议应出席董事 9 名，实际出席董事 9 名，董事会秘书及其他高级管理人员列席本次 会议。本次会议的召集和召开程序符合《公司法》和《公司章程》等有关规定，会 议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司符合向不特定对象发行可转换公司债券条件的议案》 根据《公司法》《证券法》以及《上市公司证券发行注册管理办法》等有关法 律、法规及规范性文件的规定，董事会对公司的实际情况进行了逐项自查和论证， 认为公司符合现行法律、法规和规范性文件中关于科创板上市公司向不特 ...

Group 1 - The core transaction of Te Bao Bio occurred on January 22, with a volume of 91,000 shares and a transaction amount of 6.9533 million yuan, at a price of 76.41 yuan per share [2][4] - In the last three months, Te Bao Bio has recorded a total of 7 block trades, amounting to 57.4718 million yuan [3] - The closing price of Te Bao Bio on the day of the transaction was 76.41 yuan, reflecting a decrease of 2.20%, with a daily turnover rate of 0.52% and a total transaction amount of 163 million yuan [3] Group 2 - The latest margin financing balance for Te Bao Bio is 1.373 billion yuan, with a decrease of 8.1317 million yuan over the past five days, representing a decline of 0.59% [4] - The company, Xiamen Te Bao Bioengineering Co., Ltd., was established on August 7, 1996, with a registered capital of 4.0818948 billion yuan [4]

Group 1 - The core transaction involved 91,000 shares of TEBIO, with a total transaction value of 6.9533 million yuan, representing 4.1% of the total trading volume for the day [1][2] - The transaction price was 76.41 yuan, which was consistent with the market closing price on that day [1][2]

Core Viewpoint - The A-share market experienced fluctuations on January 22, with the Shanghai Composite Index rising by 0.14%. The innovative drug sector faced pressure, as evidenced by the decline of the Science and Technology Innovation Drug ETF Huatai (589120) by 1.51% by 15:00. However, the ETF saw a net inflow of funds totaling 27.7361 million yuan over the past three days, indicating a trend of buying on dips [1]. Group 1: Market Performance - The Science and Technology Innovation Drug ETF Huatai (589120) recorded a net inflow of 27.7361 million yuan over three days, showing a clear trend of increased buying despite market declines [1]. - By 15:00, the ETF's component stocks exhibited mixed performance, with notable gains from Kangxinuo at 1.81%, Baiaotai at 0.49%, and Haoyuan Pharmaceutical at 0.48%. Conversely, Yifang Bio fell over 6%, Rongchang Bio dropped over 4%, and Baili Tianheng decreased by over 3% [6]. Group 2: Industry Insights - According to the National Medical Insurance Administration, 76 innovative drugs are expected to be approved for market entry by the National Medical Products Administration by 2025, marking a record high and indicating a trend towards diversified innovative therapies in China [4]. - Donghai Securities predicts that the innovative drug sector is entering a new era, transitioning from a generics-dominated market (pre-2018) to a period of transformation (2018-2025) characterized by price reductions and increased R&D investments in innovative drugs. By 2026, innovative drugs are expected to dominate the pharmaceutical industry in China, supported by complementary insurance policies and a focus on the pace of new drug launches and competitive dynamics [5].

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Summary of Semiconductor Equipment Industry Conference Call Industry Overview - The semiconductor equipment industry is experiencing a supply-demand imbalance, particularly in storage solutions, driven by the surge in artificial intelligence (AI) demand. This situation is expected to persist for some time, affecting both enterprise and consumer-grade solid-state drives (SSDs) [1][2]. Key Companies and Insights Kioxia - Kioxia's storage division manager, Jun Saito, indicated that the supply-demand tightness will continue, leading to shortages in both enterprise and consumer SSDs [1][2]. Jinhai Tong - Focuses on the translation sorting machine, benefiting from the launch of the 9000 series three-temperature sorting machine, which has significantly increased automotive electronics revenue. The company is also developing high-end sorting machines for AI chips, anticipating substantial order breakthroughs in 2026 with projected revenues of 14 billion and profits of 5 billion [3]. Huafeng Measurement and Control - The 8600 GPU testing machine is leading in testing channel count, frequency, and parallel processing capabilities domestically. Small-scale production validation has been completed, with a high likelihood of securing large orders in 2026 [3]. Jingce Electronics - The company has seen significant order growth, especially in Hefei, with expectations for continued growth in 2026. It leads in fields such as film thickness, OCD, and electron beam technologies, with advancements in 14nm technology expected this year [3]. Qiangyi Co., Ltd. - The company has engaged with major clients in the computing chip sector and has completed deliveries or initial validations of 2.5D MEMS probe cards for HBM, NOR Flash, and DRAM. With overseas probe card shortages, the company is expected to exceed performance expectations in 2026 [3]. Changchuan Technology - Deeply integrated with H, the storage testing machine is set for a breakout year, with expected revenues of 15 billion. The GPU testing machine holds a significant market share in H's computing chip testing, with strong order backlogs [4]. Jingzhida - A leader in high-speed FT testing machines, the company is actively validating its products with clients, expecting to double orders and revenue this year, driven by two storage products [4]. Weida Nano - Primarily serving two storage clients, the company has seen a doubling of new orders in 2025, with mature products gaining traction among new clients and expectations for order upgrades in 2026 [4]. Maiwei Co., Ltd. - Focused on etching and ALD in the semiconductor sector, the company anticipates approximately 8 billion in front-end equipment orders for 2025, with two-thirds attributed to storage. The target for front-end orders in 2026 is set at 20 billion, with an optimistic outlook for continued growth [4]. Additional Insights - The semiconductor equipment sector is poised for growth due to increased capital expenditures in domestic and international fabs, indicating a robust investment environment [1][2]. - The ongoing demand for AI and related technologies is expected to drive further advancements and opportunities within the industry [1][2].

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Group 1 - The core point of the article is that TeBao Bio announced the renewal of the "Joint Action Agreement" between its actual controllers, Yang Ying and Sun Li, to ensure the company's stable development and operational continuity [2][3] - The renewal of the agreement was prompted by the impending expiration of the previous agreement signed on January 16, 2023 [2] - The company aims to promote steady growth and safeguard operational stability through this renewed agreement [2]